ASPREE Cancer Endpoints Study

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Cancer

In brief

The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for the examination of the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases. The establishment of this ACES biobank will allow for the exploration of DNA-related molecular mechanisms of aspirin's protective effect against cancer, cancer associated mortality and metastases, using blood or saliva DNA specimens, urine, and tumor tissue.

Key facts

Study ID
NCT01968798
Run by
Hennepin Healthcare Research Institute
People needed
14500
Starts
2013-09-01
Expected to finish
2024-04-01
Last updated by the study team
2021-04-05

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.